Skip to main content Accessibility help
×
Home

CHALLENGES FACED IN TRANSFERRING ECONOMIC EVALUATIONS TO MIDDLE INCOME COUNTRIES

  • Michael Drummond (a1), Federico Augustovski (a2), Zoltán Kaló (a3), Bong-Min Yang (a4), Andres Pichon-Riviere (a2), Eun-Young Bae (a5) and Sachin Kamal-Bahl (a6)...

Abstract

Background: Decision makers in middle-income countries are using economic evaluations (EEs) in pricing and reimbursement decisions for pharmaceuticals. However, whilst many of these jurisdictions have local submission guidelines and local expertise, the studies themselves often use economic models developed elsewhere and elements of data from countries other than the jurisdiction concerned. The objectives of this study were to describe the current situation and to assess the challenges faced by decision makers in transferring data and analyses from other jurisdictions.

Methods: Experienced health service researchers in each region conducted an interview survey of representatives of decision making bodies from jurisdictions in Asia, Central and Eastern Europe, and Latin America that had at least 1 year's experience of using EEs.

Results: Representatives of the relevant organizations in twelve countries were interviewed. All twelve jurisdictions had developed official guidelines for the conduct of EEs. All but one of the organizations evaluated studies submitted to them, but 9 also conducted studies and 7 commissioned them. Nine of the organizations stated that, in evaluating EEs submitted to them, they had consulted a study performed in a different jurisdiction. Data on relevant treatment effect was generally considered more transferable than those on prices/unit costs. Views on the transferability of epidemiological data, data on resource use and health state preference values were more mixed. Eight of the respondents stated that analyses submitted to them had used models developed in other jurisdictions. Four of the organizations had a policy requiring models to be adapted to reflect local circumstances. The main obstacles to transferring EEs were the different patterns of care or wealth of the developed countries from which most economic evaluations originate.

Conclusions: In middle-income countries it is commonplace to deal with the issue of transferring analyses or data from other jurisdictions. Decision makers in these countries face several challenges, mainly due to differences in current standard of care, practice patterns, or gross domestic product between the developed countries where the majority of the studies are conducted and their own jurisdiction

Copyright

References

Hide All
1. Drummond, MF, Twenty years of using economic evaluations for drug reimbursement decisions. What has been achieved? J Health Polit Policy Law. 2013;38:10811102.
2. Drummond, MF, Sculpher, MJ, Claxton, K, Torrance, GW, Stoddart, GL. Methods for the economic evaluation of health care programmes: Fourth edition. Oxford: Oxford University Press; 2015.
3. Tsuchiya, A, Williams, A. Welfare economics and economic evaluation. In: Drummond M, McGuire A, eds. Economic evaluation in health care: Merging theory with practice. Oxford: Oxford University Press; 2001.
4. Coast, J. Is economic evaluation in touch with society's health values? BMJ. 2004;329:12331236.
5. Shiell, A, Hawe, P, Gold, L. Complex interventions or complex systems. Implications for economic evaluation. BMJ. 2008;336:1281.
6. Drummond, M, Barbieri, M, Cook, J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009;12:409418.
7. Barbieri, M, Drummond, M, Rutten, F, et al. What do international pharmacoeconomic guidelines say about economic data transferability? Value Health. 2010;13:10281037.
8. Caro, JJ, Briggs, AH, Siebert, U, et al. Modeling good research practices - overview: A report of the ISPOR-SMDM modeling good research practices task force-1. Value Health. 2012;15:796803.
9. Eunethta. (2013) EuNetHTA adaptation toolkit http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/EUnetHTA_adptation_toolkit_2011%20version%205.pdf (accessed December 5, 2013).
10. Goeree, R, Burke, N, O'Reilly, D, et al. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin. 2007;23:671682.
11. Augustovski, F, Iglesias, C, Manca, A, et al. Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. Pharmacoeconomics. 2009;27:919929.
12. Pichon-Riviere, A, Augustovski, F, García Martí, S, Sullivan, SD, Drummond, M. Transferability of health technology assessment reports in Latin America: an exploratory survey of researchers and decision makers. Int J Technol Assess Health Care. 2012;28:180186
13. Neumann, PJ, Drummond, MF, Jönsson, B, et al. Are key principles for improved health technology assessment supported and used by health technology assessment organizations? Int J Technol Assess Health Care. 2010;26:7178.
14. Drummond, MF, Neumann, PJ, Jönsson, B, et al. Can we reliably benchmark health technology assessment organizations? Int J Technol Assess Health Care. 2012;28:159165.
15. Jansen, JP, Fleurence, R, Devine, B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on indirect treatment comparisons good research practices: Part 1. Value Health. 2011;14:417428.
16. Hoaglin, DC, Hawkins, N, Jansen, JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: Report of the ISPOR Task Force on indirect treatment comparisons good research practices—Part 2. Value Health. 2011;14:429437.

Keywords

Type Description Title
WORD
Supplementary materials

Drummond supplementary material S1
TRANSFERABILITY OF HTA QUESTIONNAIRE V2

 Word (27 KB)
27 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed